Despite Target Cuts, Analysts Stick With Incyte for Big Upside

Health and Healthcare

Published: January 30, 2016 10:10 am

Last Updated: January 13, 2020 1:53 pm

Incyte Corp. (NASDAQ: INCY) took it on the chin this past week following the announcement that its Phase 2 trial of ruxolitinib would be stopped. This was detrimental to the stock, but a few analysts took a deeper look at it and realized that it might not be as bad as initially thought.

On Wednesday, the company announced that the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib in patients with relapsed or refractory metastatic colorectal cancer and high C-reactive protein (CRP) will be stopped early.

The decision to stop the sub-study was made after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation.

As a result, shares initially dropped as low as 14% off this level, pushing a new 52-week low. However after analysts came to bat for this biotech, shares made a healthy bounce in Friday’s trading session.

ALSO READ: Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now

A few analysts weighed in on Incyte:

Merrill Lynch maintained a Buy rating but cut its price target to $87 from $145.
Credit Suisse has an Outperform rating but lowered its price target to $102 from $110.
Jefferies has a Buy rating but cut its price target to $106 from $141.
JMP Securities has an Outperform rating and lowered its price target to $100 from $133.
JPMorgan has an Overweight rating and lowered its price target to $115 from $125.
Leerink has an Outperform rating and cut its price target to $118 from $135.
UBS has a Buy rating but lowered its price target to $110 from $135.

Shares of Incyte were trading at $70.56 on Friday’s close, with a consensus analyst price target of $116.77 (this may change) and a 52-week trading range of $64.51 to $133.62.

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.